Sugi Predict

Sugi Predict / Compounds / SCHEMBL589319

SCHEMBL589319

SCHEMBL589319

Cc1n[nH]c2cc(N(C)c3nc(Nc4cccc(S(=O)(=O)NC(C)C)c4)ncc3F)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 3/20 0.43
▸ CYP2D6 P10635 3/20 0.43
▸ CYP2C9 P11712 3/20 0.43
▸ CYP2C19 P33261 3/20 0.43
▸ KDR P35968 3/20 0.43
▸ BRD4 O60885 6/20 0.42
▸ PAK1 Q13153 2/20 0.41
▸ CDK2 P24941 5/20 0.40
▸ CCNT1 O60563 4/20 0.40
▸ CDK1 P06493 4/20 0.40
▸ CCNB1 P14635 4/20 0.40
▸ CDK9 P50750 4/20 0.40
▸ CCNA2 P20248 3/20 0.40
▸ CDK7 P50613 3/20 0.40
▸ CCNH P51946 3/20 0.40
▸ CCNE2 O96020 3/20 0.40
▸ CCNE1 P24864 3/20 0.40
▸ CCNB2 O95067 2/20 0.40
▸ CCNB3 Q8WWL7 2/20 0.40
▸ CCNA1 P78396 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30454154 1.00 CYP3A4 (0.43) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL31672454 0.85 PAK1 (0.42) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL2867774 0.85 PAK1 (0.42) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL588579 0.85 KDR (0.36) KDRPAK1MAP2K4
SCHEMBL589173 0.85 KDR (0.60) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL31672441 0.84 KDR (0.46) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL2877133 0.84 KDR (0.46) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL2873675 0.82 PAK1 (0.48) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL31672493 0.82 PAK1 (0.48) CYP3A4CYP2D6CYP2C9CYP2C19KDR
SCHEMBL589261 0.82 CDK2 (0.44) CYP3A4CYP2D6CYP2C9CYP2C19KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311825-A1 Pyrimidineamines as angiogenesis modulators GlaxoSmithKline LLC (US) 2011-04-20 — — EP claimed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US claimed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US claimed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US claimed
EP-4599890-A2 SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2025-08-13 — — EP disclosed
CN-113181362-B Medicament for preventing and/or treating amyotrophic lateral sclerosis 国立大学法人京都大学 2023-06-13 — — CN disclosed
CN-113181362-A Agent for preventing and/or treating amyotrophic lateral sclerosis 国立大学法人京都大学 2021-07-30 — — CN disclosed
EP-3789027-A1 BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2021-03-10 — — EP disclosed
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2018-01-04 — — US disclosed
EP-3246046-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2017-11-22 — — EP disclosed
US-20120277258-A1 Chemical Compounds LEO OSPREY LIMITED (JE) 2012-11-01 — — US disclosed
US-8114885-B2 Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer GLAXOSMITHKLINE LLC (US) 2012-02-14 — — US disclosed
US-7858626-B2 Pyrimidineamines as angiogenesis modulators GLAXOSMITHKLINE LLC (US) 2010-12-28 — — US disclosed
US-20100105712-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2010-04-29 — — US disclosed
US-20070292513-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-12-20 — — US disclosed
US-20070270427-A1 CHEMICAL COMPOUNDS NOVARTIS AG (CH) 2007-11-22 — — US disclosed
US-7262203-B2 Pyrimidineamines as angiogenesis modulators SMITHKLINE BEECHAM CORPORATION (US) 2007-08-28 — — US disclosed
US-20070015756-A1 Chemical compounds NOVARTIS AG (CH) 2007-01-18 — — US disclosed
US-7105530-B2 inhibitors of vascular endothelial growth factor receptor-2 kinase; pazopanib and salts; for proliferative retinopathy; anticancer SMITHKLINE BEECHAM CORPORATION (US) 2006-09-12 — — US disclosed
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators NOVARTIS AG (CH) 2004-12-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242578-A1 Pyrimidineamines as angiogenesis modulators TYMS, TYMP, DPYD CYP3A4 3720/4885CYP2D6 2590/4885CYP2C9 3727/4885
US-20070015756-A1 Chemical compounds KDR, FLT4, FLT1 CYP3A4 2882/4885CYP2D6 1791/4885CYP2C9 2815/4885
US-20100105712-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 CYP3A4 2882/4885CYP2D6 1791/4885CYP2C9 2815/4885
US-20180000771-A1 AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS WEE2, WEE1, ERBB2 CYP3A4 1754/4885CYP2D6 736/4885CYP2C9 2283/4885
US-20120277258-A1 Chemical Compounds KDR, FLT4, FLT1 CYP3A4 2882/4885CYP2D6 1791/4885CYP2C9 2815/4885
US-20070270427-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 CYP3A4 2882/4885CYP2D6 1791/4885CYP2C9 2815/4885
US-20070292513-A1 CHEMICAL COMPOUNDS KDR, FLT4, FLT1 CYP3A4 2882/4885CYP2D6 1791/4885CYP2C9 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.